All Stories

  1. Development and partial characterization of fused human endostatin
  2. Engineering and Partial Characterization of an Anti-IL-23/Anti-TNF-α Bispecific Domain Antibody Fused to Human Serum Albumin Domain for Inflammatory Disease Therapy
  3. The rise of bispecific T-cell engager (BsTCE) antibodies: A potentially game-changing approach for breast cancer therapy?
  4. Journey of therapeutic antibodies: from discovery to future
  5. Lignin-based biopharmaceuticals from nature to medicine: current trends, future prospects and emerging challenges
  6. Correction: Photosensitizer-Antibody Conjugates (PhotoBodies): Emerging Frontiers in the Field of Theranostics
  7. Radioligand–Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis
  8. Photosensitizer-Antibody Conjugates (PhotoBodies): Emerging Frontiers in the Field of Theranostics
  9. Polybodies for the treatment of respiratory syncytial virus infection
  10. Chemotherapeutic Drug—Antibody Conjugates (ChemoBodies): Recent Advances and Future Directions
  11. Challenges and advances in the development of antidotes against A-series nerve agents
  12. Efficacy and safety of transcutaneous electrical nerve stimulation versus oxybutynin in the treatment of overactive bladder in children: a systematic review and meta-analysis
  13. Cardioprotective Potential of ApoE-Derived Peptide (ApoEFrag) in Myocardial Infarction in Rats: A Mechanistic Study
  14. Amino acid deprivation vs. mainstream cancer therapeutics: exploring the potential and limitations
  15. Human Paraoxonase 1: From Bloodstream Enzyme to Disease Fighter & Therapeutic Intervention
  16. Neuroprotective potential of ApoE-mimetic peptide (ApoEFrag) in stroke models: Neurobehavioural and mechanistic study
  17. Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α
  18. Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide Therapy
  19. What are biopharmaceuticals?
  20. ApoE potential in CNS drugs targeting and as CNS therapeutic
  21. Antigen Specificity: A Fluctuating Aspect in the Development of Clinical Antibodies?
  22. Therapeutic Use of ApoE-Mimetic Peptides
  23. Endostatin in disease modulation: From cancer to beyond
  24. Role of paraoxonase 1 in organophosphate G-series nerve agent poisoning and future therapeutic strategies
  25. Polybodies: Next-generation clinical antibodies
  26. Broad-spectrum anti-cancer activity of fused human arginase variants
  27. Warfare Nerve Agents and Paraoxonase-1 as a Potential Prophylactic Therapy against Intoxication
  28. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies
  29. Treating liver cancer through arginine depletion
  30. Polyvalency: an emerging trend in the development of clinical antibodies
  31. Towards development of biobetter: L-asparaginase a case study
  32. Catalysing and Accelerating a New Phase in Indian Biopharma
  33. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics
  34. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status
  35. Development and characterization of fused human arginase I for cancer therapy
  36. Human arginase I: a potential broad-spectrum anti-cancer agent
  37. Fused human paraoxonase 1 as a prophylactic agent against organophosphate poisoning
  38. Polyspecificity - An emerging trend in the development of clinical antibodies
  39. Paraoxonase 1 as a potential prophylactic against nerve agent poisoning
  40. Types of Wound Dressings and Materials used in Mild to Moderately Exuding Wounds: A Review
  41. Apolipoprotein-mimetic Peptides: Current and Future Prospectives
  42. Immunomodulatory potential of apolipoproteins and their mimetic peptides in asthma: Current perspective
  43. Human arginase 1, a Jack of all trades?
  44. Therapeutic potential of ApoE-mimetic peptides in CNS disorders: Current perspective
  45. HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?
  46. Optimization of medium composition to increase the expression of recombinant human interferon-β using the Plackett–Burman and central composite design in E. coli SE1
  47. Human Arginase I (Arg I)—A Potential Broad-spectrum Anti-cancer Agent: Perspectives and the Road Ahead
  48. APOE-Derived Peptides Attenuated Diabetes-Induced Oxidative Stress and Inflammation
  49. Is Human Paraoxonase 1 the Saviour Against the Persistent Threat of Organophosphorus Nerve Agents?
  50. Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics
  51. Antibiotic-free expression system for the production of human interferon-beta protein
  52. Towards Understanding the Catalytic Mechanism of Human Paraoxonase 1: Experimental and In Silico Mutagenesis Studies
  53. Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead
  54. Refolded Recombinant Human Paraoxonase 1 Variant Exhibits Prophylactic Activity Against Organophosphate Poisoning
  55. Toward Understanding the Catalytic Mechanism of Human Paraoxonase 1: Site-Specific Mutagenesis at Position 192
  56. Abstract 12419: Preclinical Safety and Efficacy of a Novel Thrombolytic Agent Administered by Rapid Bolus Injection: Clot Specific Streptokinase (CSSK/SMRX-11)
  57. Improving Properties of Recombinant SsoPox by Site-Specific Pegylation
  58. Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of Escherichia coli
  59. Expression, purification and immobilization of recombinant AiiA enzyme onto magnetic nanoparticles
  60. Improving storage stability of recombinant organophosphorus hydrolase
  61. Interplay between amino acid residues at positions 192 and 115 in modulating hydrolytic activities of human paraoxonase 1
  62. Properties of apolipoprotein E derived peptide modulate their lipid-binding capacity and influence their anti-inflammatory function
  63. Stabilization Studies on Bacterially Produced Human Paraoxonase 1 for Improving Its Shelf Life
  64. Human Paraoxonase 1 as a Pharmacologic Agent: Limitations and Perspectives
  65. Apolipoprotein E Derived Peptides Inhibit the Pro-Inflammatory Effect of Lysophosphatidylcholine
  66. Oxidized-phospholipids in reconstituted high density lipoprotein particles affect structure and function of recombinant paraoxonase 1
  67. Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme
  68. Differential interaction of peptides derived from C-terminal domain of human apolipoprotein E with platelet activating factor analogs
  69. The Chemical Nature of the Polar Functional Group of Oxidized Acyl Chain Uniquely Modifies the Physicochemical Properties of Oxidized Phospholipid-Containing Lipid Particles
  70. Physicochemical properties of bacterial pro-inflammatory lipids influence their interaction with apolipoprotein-derived peptides
  71. Oxidized phospholipid content destabilizes the structure of reconstituted high density lipoprotein particles and changes their function
  72. Characterization of Oxidized Phospholipid containing Reconstituted High Density Lipoprotein Particle
  73. A Therapeutic Chemical Chaperone Inhibits Cholera Intoxication and Unfolding/Translocation of the Cholera Toxin A1 Subunit
  74. Closely related oxidized phospholipids differentially modulate the physicochemical properties of lipid particles
  75. Membrane lipid composition differentially modulates the function of human plasma platelet activating factor-acetylhydrolase
  76. Contribution of Subdomain Structure to the Thermal Stability of the Cholera Toxin A1 Subunit
  77. Oxidatively modified fatty acyl chain determines physicochemical properties of aggregates of oxidized phospholipids
  78. Stabilization of the Tertiary Structure of the Cholera Toxin A1 Subunit Inhibits Toxin Dislocation and Cellular Intoxication
  79. Peptide derived from the lipid binding domain of Group IB human pancreatic phospholipase A2 possesses antibacterial activity
  80. Membrane surface charge modulates lipoprotein complex forming capability of peptides derived from the C-terminal domain of apolipoprotein E
  81. Preferential binding of apolipoprotein E derived peptides with oxidized phospholipid
  82. Bax C-Terminal Peptide - Insights Into Membrane Interactions
  83. Conformational Instability of the Cholera Toxin A1 Polypeptide
  84. The Pertussis Toxin S1 Subunit Is a Thermally Unstable Protein Susceptible to Degradation by the 20S Proteasome
  85. Isoform-Specific Membrane Insertion of Secretory Phospholipase A2 and Functional Implications
  86. Structural and Functional Effects of Tryptophans Inserted into the Membrane-binding and Substrate-binding Sites of Human Group IIA Phospholipase A2
  87. Carbohydrate-induced modulation of cell membrane. VIII. Agglutination with mammalian lectin galectin-1 increases osmofragility and membrane fluidity of trypsinized erythrocytes
  88. Evidence for the Regulatory Role of the N-terminal Helix of Secretory Phospholipase A2 from Studies on Native and Chimeric Proteins
  89. Positioning Membrane Proteins by Novel Protein Engineering and Biophysical Approaches
  90. Membrane Fluidity Is a Key Modulator of Membrane Binding, Insertion, and Activity of 5-Lipoxygenase
  91. Modulation of Human 5-Lipoxygenase Activity by Membrane Lipids, by
  92. The N-terminal α-Helix of Pancreatic Phospholipase A2 Determines Productive-mode Orientation of the Enzyme at the Membrane Surface
  93. Modulation of Human 5-Lipoxygenase Activity by Membrane Lipids
  94. Oxidation of Goat Hepatic Galectin-1 Induces Change in Secondary Structure
  95. Involvement of a Nine-residue Loop of Streptokinase in the Generation of Macromolecular Substrate Specificity by the Activator Complex through Interaction with Substrate Kringle Domains
  96. Studies on a Doubleheaded Protease Inhibitor from Phaseolus mungo
  97. Carbohydrate induced modulation of cell membrane VII. Binding of exogenous lectin increases osmofragility of erythrocytes
  98. Carbohydrate induced modulation of cell membrane. VI. Binding of exogenous lectin induces susceptibility of erythrocytes to free radical damage: a spin label study